由于2026年2月18日股价上升,三名Exexexexexexixe执行官在收入丰厚后出售了350万美元股票。 Three Exelixis executives sold $3.5 million in stock after strong earnings, as shares rose on Feb. 18, 2026.

2026年2月17日至18日,三名Exelixis执行官——CFO Christopher Senner、SVP Brenda Hefti和一位董事——分别出售80 536股股票,共计约350万美元。 On February 17-18, 2026, three Exelixis executives—CFO Christopher Senner, SVP Brenda Hefti, and a director—sold a combined 80,536 shares, totaling about $3.5 million, in separate transactions. 这些销售是继Exelixis 2月10日的收入报告之后进行的,其中显示94美元为EPS, 猛击估计数和5.9866亿美元的收入,逐年增长5.6%。 The sales followed Exelixis’ Feb. 10 earnings report, which showed $0.94 EPS, beating estimates, and $598.66 million in revenue, up 5.6% year-over-year. 2月18日,库存增至44.47美元,数量超过平均水平。 The stock rose to $44.47 on Feb. 18, with above-average volume. 这家专注于癌症治疗的公司, 像CABOMETYX®和COMETRIQ®, 市值为115.5亿美元, 持有评级为47.11美元. The company, focused on cancer therapies like CABOMETYX® and COMETRIQ®, has a market cap of $11.55 billion and a consensus “Hold” rating with a $47.11 target.